Table 1.
Characteristics | Acute cardiotoxicity | Early-onset, chronic progressive cardiotoxicity | Late-onset, chronic progressive cardiotoxicity |
---|---|---|---|
Onset | Within the first week of anthracycline treatment | <1 year after the completion of anthracycline treatment | ≥1 year after the completion of anthracycline treatment |
Risk factor dependence | Unknown | Yesa | Yesa |
Clinical features in adults | Transient depression of myocardial contractility | Dilated cardiomyopathy | Dilated cardiomyopathy |
Clinical features in children | Transient depression of myocardial contractility | Restrictive cardiomyopathy and/or dilated cardiomyopathy | Restrictive cardiomyopathy and/or dilated cardiomyopathy |
Course | Usually reversible on discontinuation of anthracycline | Can be progressive | Can be progressive |